Molecular Mechanisms of L-DOPA-Induced Dyskinesia

Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

Abstract

The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment for Parkinson's disease (PD), but causes dyskinesias (abnormal involuntary movements) in the vast majority of patients. There is a wide consensus that L-DOPA-induced dyskinesia (LID) depends on both pre- and postsynaptic disturbances of the nigrostriatal DA transmission. Presynaptically, LID is associated with abnormal DA release and defective DA clearance, which converge to cause large swings in brain DA levels concomitant with the medication. Postsynaptically, LID is associated with a dysregulation of intracellular signaling and gene expression downstream of the D1 DA receptor. These phenomena are particularly well studied in the striatum and are thus the main topic of this chapter. In addition, the chapter reviews studies that have revealed associations between LID and different types of abnormalities in glutamatergic and GABAergic transmission within cortico-basal ganglia circuits.

Original languageEnglish
Title of host publicationHandbook of Behavioral Neuroscience
PublisherElsevier
Pages857-871
Number of pages15
Volume24
DOIs
Publication statusPublished - 2017

Publication series

NameHandbook of Behavioral Neuroscience
Volume24
ISSN (Print)15697339

Subject classification (UKÄ)

  • Neurosciences

Free keywords

  • animal models
  • dopamine
  • gene expression
  • glutamate
  • Neurodegenerative disease
  • neuroplasticity
  • Parkinson's disease
  • serotonin
  • striatum

Fingerprint

Dive into the research topics of 'Molecular Mechanisms of L-DOPA-Induced Dyskinesia'. Together they form a unique fingerprint.

Cite this